Sökning: WFRF:(Ruffin N.) >
B-cell repopulation...
-
Asplund Högelin, K.Karolinska Institutet
(författare)
B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
2022-07-20
-
Wiley,2022
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:kth-325694
-
https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-325694URI
-
https://doi.org/10.1111/ene.15492DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:150242579URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
QC 20230412
-
Background and purpose: Recent findings document a blunted humoral response to SARS-CoV-2 vaccination in patients on anti-CD20 treatment. Although most patients develop a cellular response, it is still important to identify predictors of seroconversion to optimize vaccine responses. Methods: We determined antibody responses after SARS-CoV-2 vaccination in a real-world cohort of multiple sclerosis patients (n = 94) treated with anti-CD20, mainly rituximab, with variable treatment duration (median = 2.9, range = 0.4–9.6 years) and time from last anti-CD20 infusion to vaccination (median = 190, range = 60–1032 days). Results: We find that presence of B cells and/or rituximab in blood predict seroconversion better than time since last infusion. Using multiple logistic regression, presence of >0.5% B cells increased probability of seroconversion with an odds ratio (OR) of 5.0 (95% confidence interval [CI] = 1.0–28.1, p = 0.055), whereas the corresponding OR for ≥6 months since last infusion was 1.45 (95% CI = 0.20–10.15, p = 0.705). In contrast, detectable rituximab levels were negatively associated with seroconversion (OR = 0.05, 95% CI = 0.002–0.392, p = 0.012). Furthermore, naïve and memory IgG+ B cells correlated with antibody levels. Although retreatment with rituximab at 4 weeks or more after booster depleted spike-specific B cells, it did not noticeably affect the rate of decline in antibody titers. Interferon-γ and/or interleukin-13 T-cell responses to the spike S1 domain were observed in most patients, but with no correlation to spike antibody levels. Conclusions: These findings are relevant for providing individualized guidance to patients and planning of vaccination schemes, in turn optimizing benefit–risk with anti-CD20.
Ämnesord och genrebeteckningar
-
MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Neurologi hsv//swe
-
MEDICAL AND HEALTH SCIENCES Clinical Medicine Neurology hsv//eng
-
B-cell depletion
-
multiple sclerosis
-
rituximab
-
SARS-CoV-2
-
vaccination
-
elasomeran
-
gamma interferon
-
interleukin 13
-
nucleocapsid protein
-
ocrelizumab
-
ofatumumab
-
SARS-CoV-2 vaccine
-
tozinameran
-
adult
-
antibody response
-
antibody titer
-
Article
-
B lymphocyte
-
cohort analysis
-
controlled study
-
demographics
-
female
-
human
-
human cell
-
immunophenotyping
-
limit of detection
-
major clinical study
-
male
-
pre B lymphocyte
-
retreatment
-
seroconversion
-
T lymphocyte subpopulation
-
treatment duration
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Ruffin, N.Karolinska Institutet
(författare)
-
Pin, ElisaKTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab(Swepub:kth)u1pmjyje
(författare)
-
Hober, Sophia,Professor,1965-KTH,Science for Life Laboratory, SciLifeLab,Proteinteknologi(Swepub:kth)u11qqzc1
(författare)
-
Nilsson, PeterKTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik(Swepub:kth)u1ws88sk
(författare)
-
Starvaggi Cucuzza, C.Karolinska Institutet
(författare)
-
Khademi, M.Karolinska Institutet
(författare)
-
Olsson, T.Karolinska Institutet
(författare)
-
Piehl, F.
(författare)
-
Al Nimer, F.Karolinska Institutet
(författare)
-
Karolinska InstitutetAffinitets-proteomik
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European Journal of Neurology: Wiley29:11, s. 3317-33281351-51011468-1331
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Asplund Högelin, ...
-
Ruffin, N.
-
Pin, Elisa
-
Hober, Sophia, P ...
-
Nilsson, Peter
-
Starvaggi Cucuzz ...
-
visa fler...
-
Khademi, M.
-
Olsson, T.
-
Piehl, F.
-
Al Nimer, F.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Kungliga Tekniska Högskolan
-
Karolinska Institutet